Agents targeting specific molecular pathways identified in chordoma pathogenesis, such as platelet-derived growth factor receptor (PDGFR), epidermal growth factor receptor (EGFR), and mammalian target of rapamycin (mTOR) pathways, are under investigation and hold promise for improving outcomes in patients with metastatic disease​​ [4]. This evidence concerns the gene MTOR and metastatic neoplasm.